Bioequivalence Studies and Assessment

Bioequivalence studies determine whether two drug products deliver comparable systemic exposure and can therefore be regarded as interchangeable. They typically compare a test product with a reference using a crossover design and judge equivalence statistically: the confidence interval for the ratio of exposure metrics must fall within predefined limits. This logic is the scientific foundation of generic-drug approval and product interchangeability.

Definition

A bioequivalence study is a comparative pharmacokinetic investigation that tests whether the rate and extent of absorption of a test product differ from a reference product by no more than predefined limits, usually by requiring the 90% confidence interval for the ratio of log-transformed exposure metrics to lie within accepted bounds.

Scope

The entry covers the rationale for bioequivalence testing, the crossover study design and exposure metrics it uses, the two one-sided tests procedure and equivalence-interval logic that govern its conclusions, and the distinction between average, population, and individual bioequivalence. It treats assessment methodology as a reference topic in biopharmaceutics and regulatory science, not as substitution or prescribing guidance.

Core questions

• When can two products be declared interchangeable?
• Which exposure metrics and study design are used to compare them?
• How does the two one-sided tests procedure establish equivalence rather than difference?
• How do average, population, and individual bioequivalence differ?

Key concepts

• Test versus reference product
• Crossover design
• Log-transformed AUC and Cmax
• 90% confidence interval and equivalence limits
• Average, population, and individual bioequivalence
• Biowaivers and the Biopharmaceutics Classification System

Key theories

Two one-sided tests (TOST) equivalence framework

Equivalence is concluded only if both one-sided hypotheses of meaningful difference are rejected, operationalised by requiring the 90% confidence interval of the test-to-reference exposure ratio to fall entirely within predefined equivalence limits; this reframes the question from detecting a difference to demonstrating similarity.

Mechanisms

A typical bioequivalence study administers the test and reference products to the same volunteers in a randomised crossover, measures plasma concentrations, and derives exposure metrics: area under the concentration-time curve for extent and peak concentration for rate. These metrics are log-transformed and analysed with the two one-sided tests procedure, which concludes equivalence only when the 90% confidence interval for the test-to-reference geometric mean ratio lies entirely within the accepted equivalence interval. Average bioequivalence compares mean exposures; population and individual bioequivalence criteria additionally consider variability and within-subject switchability, though average bioequivalence remains the standard approach. For certain highly soluble, highly permeable drugs, biowaiver frameworks grounded in the Biopharmaceutics Classification System allow in vitro dissolution data to substitute for an in vivo study.

Clinical relevance

Bioequivalence assessment is the scientific basis for substituting a generic product for an innovator and for approving formulation changes without repeating full clinical trials. It is a reference framework for understanding how interchangeability is demonstrated; it characterises product-level evidence and is not a basis for individual substitution or dosing decisions.

Evidence & guidelines

Regulatory bioequivalence relies on the two one-sided tests procedure formalised by Schuirmann, with conventional equivalence limits applied to log-transformed exposure ratios. Chen and colleagues set out the regulatory considerations behind individual bioequivalence criteria, while the Biopharmaceutics Classification System of Amidon and colleagues underlies biowaiver policy. Davit and colleagues' review of twelve years of United States approval data found that observed differences between generic and innovator products clustered closely around the reference, illustrating the practical performance of the framework.

History

Concern that nominally identical products could differ in absorption drove the creation of formal bioequivalence testing in the late twentieth century. Schuirmann's 1987 articulation of the two one-sided tests procedure gave the field its dominant statistical method, shifting the question from detecting a difference to demonstrating equivalence. Subsequent debate over population and individual bioequivalence criteria, reviewed by Chen and colleagues, refined but did not displace the average-bioequivalence standard, and the Biopharmaceutics Classification System later enabled biowaivers for suitable drugs.

Debates

Is average bioequivalence sufficient, or are individual criteria needed?

Average bioequivalence compares mean exposures but does not directly address within-subject switchability or differences in variability; individual and population bioequivalence criteria were proposed to capture these, yet they add complexity and have not replaced the average-bioequivalence standard.

Key figures

• Donald Schuirmann
• Mei-Ling Chen
• Gordon Amidon
• Barbara Davit

Seminal works

• schuirmann-1987
• chen-2000

Frequently asked questions

What does it mean for two products to be bioequivalent?

It means their rate and extent of absorption are similar enough that the confidence interval for the ratio of their exposure metrics falls within predefined equivalence limits, supporting the conclusion that they deliver comparable systemic exposure.

Why are bioequivalence data log-transformed and analysed with two one-sided tests?

Exposure metrics are multiplicative and approximately log-normal, so log transformation stabilises the analysis, and the two one-sided tests procedure is designed to demonstrate equivalence within limits rather than merely to detect a difference.